aquanil 2.5 mg/ml silmätipat, liuos
omnivision ab - timololi maleas - silmätipat, liuos - 2.5 mg/ml - timololi
aquanil 5 mg/ml silmätipat, liuos
omnivision ab - timololi maleas - silmätipat, liuos - 5 mg/ml - timololi
ranivisio
midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
gyno-daktarin 2 % emätinvoide
mcneil, a division of janssen- cilag oy - miconazoli nitras - emätinvoide - 2 % - mikonatsoli
gyno-daktarin 400 mg emätinpuikko, kapseli, pehmeä
mcneil, a division of janssen-cilag oy - miconazole nitrate - emätinpuikko, kapseli, pehmeä - 400 mg - mikonatsoli
rogaine 20 mg/ml liuos iholle
mcneil, a division of janssen- cilag oy - minoxidilum - liuos iholle - 20 mg/ml - minoksidiili
benadryl 8 mg kapseli, kova
mcneil, a division of janssen-cilag oy - acrivastine - kapseli, kova - 8 mg - akrivastiini
visclear 0.5 mg/ml silmätipat, liuos
mcneil, a division of janssen- cilag oy - tetryzolini hydrochloridum - silmätipat, liuos - 0.5 mg/ml - tetrytsoliini
nizoral 2 % emulsiovoide
mcneil, a division of janssen- cilag oy - ketoconazole - emulsiovoide - 2 % - ketokonatsoli
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.